A Phase 3 Open-Label, Randomized, Multicenter Study Of Nktr-102 Versus Treatment Of Physician¿s Choice (Tpc) In Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases And Have Been Previously Treated With An Anthracycline, A Taxane, And Capecitabine